Objective Studies assessing outcome improvements over a long period according to
systemic therapy strategies for metastatic renal cell carcinoma using real-world data …

Background Knowledge of changes in the outcome in patients with metastatic renal cell
carcinoma from the molecular-targeted therapy era to the immune checkpoint inhibitor (ICI) …

Background Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly
expanding, and immunotherapy using checkpoint inhibitors is a first-or second-line option …

Background: Nowadays, different therapeutic options are available for the first-line treatment
of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line …

Background Several novel immune checkpoint inhibitor (ICI)-based treatments exhibited
promising survival benefits for metastatic renal cell carcinoma (mRCC), yet there is no …

Abstract Background & Aims The average five-year survival of metastatic renal cell
carcinoma (mRCC) is 71%. However, there is significant variability in patient prognosis …

330 Background: Immune checkpoint inhibitors (ICIs) in combination with another ICI or an
antiangiogenic targeted therapy have been approved for frontline therapy in metastatic renal …

BACKGROUND To the authors' knowledge, outcomes and prognostic tools have yet to be
clearly defined in patients with metastatic renal cell carcinoma (mRCC) who are treated with …

Introduction: The aim of this retrospective study was to elucidate predictors of survival in
metastatic renal cell carcinoma (mRCC) patients in an International Metastatic Renal Cell …

Objectives To investigate the long-term follow-up outcomes of nivolumab monotherapy for
previously treated metastatic renal cell carcinoma, using real-world data. Methods A total of …